ESR1 H524L

CI-VAR-00001922Explore in graph →CIViC 5314

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Breast Neoplasm1
ESR1 Y537S OR ESR1 H524L	Selective Estrogen Receptor Covalent Antagonist H3B-6545	Predictive	D	Supports Sensitivity Response	3	submitted	EID12639 In ERα-positive breast cancer xenograft and PDX models expressing ERαWT or ERαY537S (ST986, ST1799, ST941, ST2177, ST2056), oral H3B-6545 produced dose-dependent antitumor activity, including TGI of 6… (full text at CIViC) PMID 35642432 · Furman et al., 2022 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.